Cancer Research

As part of a breast-cancer diagnosis, doctors analyze the tumor to determine which therapies might best attack the malignancy. But for patients whose cancer is triple-negative — that is, lacking receptors for estrogen, progesterone and Her2 — the options for treatment dwindle. Triple-negative cancers, or TNBC, also tend to be more aggressive than other cancer subtypes.

Katherine Unger Baillie ・February 2, 2018

Breast cancer mortality rates have steadily declined over the past few decades, thanks to a combination of early detection and improved treatments. But for patients diagnosed with triple-negative breast cancer (TNBC), a subtype in which tumor cells lack receptors for estrogen, progesterone, and Her2, no targeted treatments are available.

Katherine Unger Baillie ・February 1, 2018

George Hajishengallis of the School of Dental Medicine and an international team of colleagues have found that “training” the immune system causes changes in the precursors of immune cells in the bone marrow. These changes could facilitate a more robust response to future infections or even enable the immune system to regenerate faster after chemotherapy.

Katherine Unger Baillie ・January 12, 2018

A comprehensive dental visit includes more than a cleaning and X-rays; well-trained dentists know they must also take a thorough look inside the oral cavity to spot any potentially unusual lesions that could signal oral cancer.

Katherine Unger Baillie ・November 30, 2017

Cancer of the pancreas is rare, but deadly. Research from Penn Vet may slow its spread.

Katherine Unger Baillie ・November 2, 2017

Cancer of the pancreas is a deadly disease, with a median survival time of less than six months. Only one in 20 people with pancreatic cancer survives five years past the diagnosis. The reason is the cancer’s insidiousness; tumor cells hide deep inside the body, betraying no symptoms until late in the disease, when the cancer has almost invariably spread to other organs.

Katherine Unger Baillie ・October 27, 2017

Investigators at the Perelman School of Medicine and CHOP, who together led research, development, and clinical trials of the new therapy in collaboration with Novartis, hail the FDA’s approval as a game changer for the treatment of younger patients battling the aggressive blood cancer and a pivotal milestone in this new era of cellular therapies.

August 30, 2017

As many as 115 patients treated each day. Upwards of 5,000 people who have received life-saving cancer care since 2010. As impressive as these numbers are, the outcomes at the Roberts Proton Therapy Center are even more so.

Christina Cook July 28, 2017